JP2019505511A - 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 - Google Patents

悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 Download PDF

Info

Publication number
JP2019505511A
JP2019505511A JP2018534782A JP2018534782A JP2019505511A JP 2019505511 A JP2019505511 A JP 2019505511A JP 2018534782 A JP2018534782 A JP 2018534782A JP 2018534782 A JP2018534782 A JP 2018534782A JP 2019505511 A JP2019505511 A JP 2019505511A
Authority
JP
Japan
Prior art keywords
cell
cells
expression
activity
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018534782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505511A5 (https=
Inventor
イディット シャチャール，
イディット シャチャール，
ハダス レヴィンスキー，
ハダス レヴィンスキー，
リヒ ラドミア，
リヒ ラドミア，
アンナ ヴィーナー，
アンナ ヴィーナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2019505511A publication Critical patent/JP2019505511A/ja
Publication of JP2019505511A5 publication Critical patent/JP2019505511A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018534782A 2016-01-06 2017-01-05 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 Pending JP2019505511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275378P 2016-01-06 2016-01-06
US62/275,378 2016-01-06
PCT/IL2017/050019 WO2017118985A1 (en) 2016-01-06 2017-01-05 Compositions and methods for treating malignant, autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2019505511A true JP2019505511A (ja) 2019-02-28
JP2019505511A5 JP2019505511A5 (https=) 2020-02-13

Family

ID=58016750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534782A Pending JP2019505511A (ja) 2016-01-06 2017-01-05 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法

Country Status (7)

Country Link
US (3) US10828318B2 (https=)
EP (1) EP3400068A1 (https=)
JP (1) JP2019505511A (https=)
CN (1) CN108697907A (https=)
AU (1) AU2017204950A1 (https=)
CA (1) CA3009127A1 (https=)
WO (1) WO2017118985A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516089A (ja) * 2020-03-06 2023-04-17 アレタ・バイオセラピューティクス・インコーポレイテッド がんの治療のための組成物及び方法
JP2024514830A (ja) * 2021-04-05 2024-04-03 アルテイア サイエンス エッセ．エッレ．エッレ． 新規腫瘍特異的抗原を使用する骨髄性障害および急性白血病の診断および処置

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
RU2593715C2 (ru) 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US10760075B2 (en) * 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN111304316A (zh) * 2020-03-04 2020-06-19 苏州大学 基因Bmal1在制备检测治疗炎症性肠病的产品中的应用
CN115990252A (zh) * 2021-10-18 2023-04-21 清华大学 通过阻断slam家族受体的信号来治疗肿瘤的组合物及其应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024008659A1 (en) * 2022-07-04 2024-01-11 Institut National de la Santé et de la Recherche Médicale Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma
CN115807090B (zh) * 2022-11-17 2025-06-17 中国医学科学院肿瘤医院 Slamf9在肿瘤免疫治疗中的应用
CN119857143A (zh) * 2023-10-20 2025-04-22 天津济坤医药科技有限公司 Cd84作为治疗靶点在制备防治炎症性肠病的药物中的应用
CN119857137A (zh) * 2023-10-20 2025-04-22 天津济坤医药科技有限公司 一种抗cd84抗体在制备预防和/或治疗炎症性肠病的药物中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
GB0001309D0 (en) 2000-01-20 2000-03-08 Nestle Sa Valve arrangement
WO2001055336A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
IL152416A0 (en) * 2000-04-27 2003-05-29 Smithkline Beecham Corp Novel compounds
US20050025789A1 (en) 2001-11-09 2005-02-03 John Nieland Allogenic vaccine that contains a costimulatory polypeptide-expresing tumor cell
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
EP2067402A1 (en) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transponson-mediated mutagenesis in spermatogonial stem cells
WO2010035259A2 (en) 2008-09-23 2010-04-01 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating b-cll
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
CN109554350B (zh) 2012-11-27 2022-09-23 儿童医疗中心有限公司 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN106573976B (zh) * 2014-02-06 2020-05-05 耶达研究及发展有限公司 抗cd84抗体、包含所述抗体的组合物及其用途
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516089A (ja) * 2020-03-06 2023-04-17 アレタ・バイオセラピューティクス・インコーポレイテッド がんの治療のための組成物及び方法
JP2024514830A (ja) * 2021-04-05 2024-04-03 アルテイア サイエンス エッセ．エッレ．エッレ． 新規腫瘍特異的抗原を使用する骨髄性障害および急性白血病の診断および処置

Also Published As

Publication number Publication date
US10828318B2 (en) 2020-11-10
EP3400068A1 (en) 2018-11-14
CA3009127A1 (en) 2017-07-13
CN108697907A (zh) 2018-10-23
AU2017204950A1 (en) 2018-08-16
US11986488B2 (en) 2024-05-21
US20190015441A1 (en) 2019-01-17
WO2017118985A1 (en) 2017-07-13
US20210052626A1 (en) 2021-02-25
US20240398847A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US20240398847A1 (en) Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US20200157237A1 (en) Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
US12171783B2 (en) Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
CN114269372A (zh) 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
US20240327826A1 (en) Compositions and methods for improving t cell persistence and function
US11884717B2 (en) Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
JP2024527557A (ja) Ｂ７ｈ３を標的とする抗原結合ポリペプチド及びその応用
JP2018515069A (ja) Ｔｎｆｒｓｆ１４／ｈｖｅｍタンパク質およびその使用の方法
WO2019081591A1 (en) NK CELLS AND LYMPHOCYTES AND USES THEREOF
CN108139375A (zh) 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
US20200268707A1 (en) Methods of modulating protein exocytosis and uses of same in therapy
US20210139601A1 (en) Lymphocyte antigen cd5-like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer agonists and methods of use thereof
EP3710577A1 (en) Hematopoietic stem cells with improved properties
JP2024527537A (ja) Ｇｄ２を標的とするユニバーサルｃａｒ－ｔ細胞及びその製造方法並びに使用
US20190345446A1 (en) Compositions and methods for modulating th-17 and th-1 cell balance
US20230303712A1 (en) Methods of treating glioblastoma
Afsahi Augmentation of anti-myeloma engineered T cells by pharmacological or genetic interventions
CN118574635A (zh) 用于抑制tmigd2表达的组合物和方法
EP3107998A2 (en) Compositions and methods for treating autoimmune and inflammatory diseases
HK40072740A (en) Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
HK1254123A1 (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
HK1254123B (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210505

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210928